Putting the award page together from the records…
Putting the award page together from the records…
ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS VERSUS DPP-4 INHIBITORS FOR ALCOHOL AND SUBSTANCE USE DISORDERS IN IMPROVING HIV-RELATED OUTCOMES AND PROVIDING HEALTH BENEFITS IN PEOPLE LIVING WITH HIV
Up for re-bid: ends 2027-08-23. Recompete brief →
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
1 action since 2026-08-18. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-08-18 | 0 | $251.8K | ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS VERSUS DPP-4 INHIBITORS FOR ALCOHOL AND SUBSTANCE USE DISORDERS IN IMPROVING HIV-RELATED OUTCOMES AND PROVIDING HEALTH BENEFITS IN PEOPLE LIVING WITH HIV |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-09-30). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗